Evaluation of a new uricosuric diuretic--ticrynafen.
Ticrynafen is an orally administered diuretic that is similar to the thiazides in its therapeutic actions, but unlike the thiazides, it increases urate excretion and lowers serum uric acid levels. Ticrynafen is useful in the treatment of hypertension and in selected cases of chronic congestive heart failure. At present, it appears to be indicated primarily in patients with these disorders who have a history of gout. Patients who are currently receiving a thiazide should not have their therapy arbitrarily changed to ticrynafen because of asymptomatic hyperuricemia.
D004232:Diuretics / Q000627:therapeutic use*; D004341:Drug Evaluation; D006016:Glycolates / Q000627:therapeutic use*; D006073:Gout / Q000517:prevention & control; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D013989:Ticrynafen / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood / Q000652:urine; D014528:Uricosuric Agents / Q000627:therapeutic use*
D004232:Diuretics; D006016:Glycolates; D014528:Uricosuric Agents; D014527:Uric Acid; D013989:Ticrynafen